Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

TEVA PHARMACEUTICALS USA, INC.

UEI: NEN9A34LRHJ5CAGE: 3V8D7

TEVA PHARMACEUTICALS USA, INC. is a federal contractor, registered under UEI NEN9A34LRHJ5 and CAGE code 3V8D7. It has been awarded $281,746,140 in federal contracts. Primary work spans Pharmaceutical Preparation Manufacturing, Research and Development in the Physical, Engineering, and Life Sciences, and Unknown NAICS. Top awarding agencies include Department Of Defense, Department Of Veterans Affairs, and Other agencies (1 agencies, <0.5% each).

Contact Information

Registration and classification details

Registration

UEI Code

NEN9A34LRHJ5

CAGE Code

3V8D7

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationForeign OwnedManufacturer of Goods

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Teva Pharmaceuticals USA, Inc. specializes in the manufacturing of pharmaceutical preparations for defense and veteran health programs, with a demonstrated focus on advanced biological formulations including adenovirus-based therapeutics. The company leverages GMP-compliant production capabilities t...

Teva Pharmaceuticals USA, Inc. specializes in the manufacturing of pharmaceutical preparations for defense and veteran health programs, with a demonstrated focus on advanced biological formulations including adenovirus-based therapeutics. The company leverages GMP-compliant production capabilities to develop, scale, and deliver complex viral vector products, demonstrating deep expertise in aseptic processing, viral vector purification, and lyophilization technologies. Their technical proficiency extends to the end-to-end manufacturing lifecycle of investigational and licensed biologics, with particular strength in meeting stringent military and VA requirements for stability, potency, and batch consistency under controlled environmental conditions. This positions them as a trusted producer of mission-critical immunotherapeutics and prophylactic agents for operational readiness. The contractor maintains a sustained relationship with the Department of Defense, consistently supplying specialized pharmaceuticals for force protection and infectious disease mitigation, and also supports the Department of Veterans Affairs with therapeutics aligned to veteran health priorities. Their work reflects a pattern of responsive, high-integrity delivery for time-sensitive, mission-essential biological products. Operating under NAICS 325412, Teva is firmly positioned in the pharmaceutical preparation manufacturing sector, with a vertical specialization in viral vector and biologic drug products. Their market presence is defined by precision manufacturing for defense and public health applications, distinguishing them as a niche supplier of complex biologics rather than conventional small-molecule drugs. As a 2L entity headquartered in Parsippany, New Jersey, Teva Pharmaceuticals USA, Inc. operates as a large-scale, regulated manufacturer without active government certifications. Their geographic footprint and infrastructure are optimized for federal supply chain demands, with a clear focus on sustaining secure, scalable production for national security and veteran healthcare missions.

Key Performance Metrics

Awards Count

819

All time

Active

0

Currently performing

Completed

804

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with TEVA PHARMACEUTICALS USA, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for TEVA PHARMACEUTICALS USA, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in TEVA PHARMACEUTICALS USA, INC.'s top NAICS codes and agencies

NAICS: 332812
New
Federal
Area of Interest (AoI) – Metal Cleaning and Finishing Services
Solicitation # W911KF25SC002-AoI0016
The Army Contracting Command Anniston Army Depot is seeking innovative commercial solutions for depot-level metal cleaning, surface preparation, and finishing services for combat vehicle components. This requirement, issued under solicitation W911KF25SC002-AoI0016, encompasses chemical stripping, alkaline immersion cleaning, and abrasive media cleaning to remove paint, corrosion, scale, and carbon. The scope includes a wide array of plating and coating processes such as anodizing, chromate conversion, black oxide, electroless nickel, hard chrome, zinc, tin, copper, and phosphate. The government anticipates utilizing a Multiple Award Task Order Contract structure to ensure technical redundancy and coverage. Key performance requirements include a strict seven-working-day turnaround time and the contractor's responsibility for the secure pick-up and delivery of parts to and from the depot in Alabama. Offerors must demonstrate significant facility capabilities, including specific tank and oven dimensions, crane clearances, and the capacity to handle high-volume part streams of varying sizes. A rigorous quality assurance approach is mandatory, requiring the ability to perform various ASTM and MIL-SPEC tests, such as salt spray, adhesion, and hydrogen embrittlement, either in-house or through certified laboratories. Evaluation will be based on technical feasibility, the safety and efficiency of cleaning methods, innovation in eco-friendly processing, and the robustness of quality control systems. Additionally, the government will assess the offeror's track record with hazardous material management and compliance with environmental regulations. Interested parties must submit a written Solution Brief by October 28, 2026, including a Rough Order of Magnitude or unit pricing structure for evaluation.
Department Of Defense

POSTED

about 10 hours ago

DEADLINE

in 8 days
View Details